Does Retatrutide Cause Nausea? Trial Data

Retatrutide, an investigational triple hormone receptor agonist developed by Eli Lilly, does cause nausea in a notable proportion of clinical trial participants. Published Phase 2 trial data reported in the New England Journal of Medicine identified nausea as one of the most common adverse events, alongside vomiting, diarrhoea and constipation. These effects were generally mild to moderate and most frequent during dose escalation. Retatrutide has no UK marketing authorisation and is available only within authorised clinical trials. This article summarises what trial data currently show about nausea and related gastrointestinal effects.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide is an investigational triple agonist medicine with no UK marketing authorisation; it can only be used within an authorised clinical trial and is not available through the NHS.

Retatrutide has no marketing authorisation in the UK or anywhere else in the world, and it can be used only within an authorised clinical trial.^[7] It is an investigational medicine developed by Eli Lilly that acts simultaneously on three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[1][2] This triple agonist mechanism is proposed to reduce appetite, support energy balance and improve glucose metabolism; these are mechanistic hypotheses based on preclinical and early-phase trial data, and the clinical significance of each effect in humans is still being established.

Because retatrutide holds no UK marketing authorisation, the Medicines and Healthcare products Regulatory Agency (MHRA) has not evaluated it for routine clinical use, and NICE has issued no guidance on it. It is not available through the NHS, and no licensed supply route exists outside a clinical trial. Anyone who encounters retatrutide being sold or offered online is not being offered a licensed medicine, and the product may be falsified or unsafe.

For people interested in medically supervised weight management, licensed treatments do exist and can be discussed with a GP. Retatrutide itself remains a subject of ongoing research, and no timeline for a UK marketing authorisation application can be given.

What do clinical trials say about retatrutide's gastrointestinal side effects?

Phase 2 trial data show nausea, vomiting, diarrhoea and constipation are the most common adverse events, generally mild to moderate and most frequent during dose escalation.

Clinical trial data indicate that nausea is among the most commonly reported side effects of retatrutide, consistent with the gastrointestinal profile seen across the GLP-1 receptor agonist class. Published findings from the Phase 2 trial reported in the New England Journal of Medicine (2023) showed that nausea, vomiting, diarrhoea and constipation were the most frequently occurring adverse events across all dose groups studied. These effects were generally described as mild to moderate in severity and tended to occur most often during dose escalation periods.^[1][2] Most participants who experienced nausea did not discontinue the trial because of it, though discontinuation due to gastrointestinal events did occur in a proportion of participants, particularly at higher dose levels.

Phase 3 data are now becoming available. The TRANSCEND-T2D-1 trial, which studied retatrutide in people with type 2 diabetes, has reported results including gastrointestinal tolerability findings; nausea and vomiting remained the most common adverse events and followed a similar dose-dependent pattern to that seen in Phase 2. The broader TRIUMPH programme, which includes several Phase 3 obesity trials, is also reporting results, and these will provide larger and longer-term data on gastrointestinal tolerability across a wider population.^[4][5] As further results are published, the picture of frequency, severity and duration of nausea and related symptoms will become clearer.

As with other medicines in this class, the pattern of nausea appearing early in treatment and then diminishing over time was observed in trial data, though individual responses varied.^[1][2] All findings come from trial populations under controlled conditions and may not reflect the full range of responses in a general clinical setting.

Who is more likely to feel sick when taking retatrutide?

Participants receiving higher doses or undergoing faster dose escalation reported nausea more frequently; individual gastrointestinal sensitivity and dietary habits around dosing may also increase susceptibility.

Trial data suggest that the likelihood of experiencing nausea with retatrutide is higher during dose escalation and at higher dose levels, meaning that participants receiving larger doses reported gastrointestinal symptoms more frequently than those on lower doses. This dose-dependent pattern is consistent with what is observed with other GLP-1 receptor agonist medicines, such as semaglutide and liraglutide, where the rate of dose increase and the final maintenance dose both influence tolerability.^[8][9]

Certain individual factors may also influence susceptibility to nausea. Based on guidance for licensed GLP-1 receptor agonists, eating large meals or high-fat foods around the time of dosing is associated with greater gastrointestinal discomfort; this is class-based advice extrapolated from licensed medicines and has not been studied specifically in retatrutide trials.^[8] People with a history of gastrointestinal sensitivity may also find symptoms more pronounced. Because retatrutide is available only within an authorised clinical trial, any questions about individual risk factors should be directed to the trial team responsible for that study. Trial participants should not adjust their dose or take over-the-counter antiemetics without first consulting the trial team, as this may affect safety monitoring and trial data.

It is important to note that retatrutide trials have excluded participants who are pregnant, breastfeeding or planning a pregnancy, and trial protocols have required participants of childbearing potential to use effective contraception. The safety and tolerability profile of retatrutide in these groups is not established.

If you are in a trial and experience persistent vomiting, are unable to keep fluids down, notice signs of dehydration (such as dizziness, dark urine or significantly reduced urination), or develop severe or persistent abdominal pain, contact your trial team promptly. For urgent concerns outside trial hours, NHS 111 can provide advice. Call 999 or go to your nearest accident and emergency department if you feel your situation is a medical emergency.

What are the safety risks of obtaining retatrutide outside a clinical trial?

Any retatrutide obtained outside an authorised trial is unregulated and may be falsified, contaminated or incorrectly dosed, carrying serious risks including infection and severe allergic reaction.

Obtaining retatrutide outside an authorised clinical trial carries serious safety risks, because retatrutide has no UK marketing authorisation and no licensed product exists for purchase. Any substance sold online or through informal channels as retatrutide is not a regulated medicine. It may contain incorrect active ingredients, harmful contaminants, incorrect concentrations or no active substance at all. Falsified injectable products in particular carry risks of infection, severe allergic reaction and other unpredictable harms.

Within an authorised clinical trial, participants are monitored by a qualified clinical team, adverse events are recorded and reported under the study protocol, and suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.^[11][12]mhra.gov.uk. This level of oversight does not exist when a product is obtained outside a trial.

If you need urgent or emergency care while taking part in a clinical trial, tell the clinicians treating you that you are a trial participant and show your trial ID card or bring your trial documentation if possible; the treating team may need to contact the trial investigators. For urgent but non-emergency health concerns, NHS 111 can provide advice. Call 999 or go to your nearest accident and emergency department in a medical emergency. For general questions about weight management options or concerns about a product you have encountered online, speak to your GP.

The MHRA has warned that advertising or selling unlicensed medicines, including pipeline weight-management treatments, is not permitted in the UK (MHRA, 18 June 2026).^[13] If you come across a website or service offering retatrutide for sale or as part of a treatment programme, this is not a legitimate or safe supply route, and you should not proceed.

Frequently Asked Questions